Association Between Vitamin D and the Development of Uterine Fibroids

Inclusion Criteria: * 1\. Patients are willing to cooperate with the follow-up and sign informed consent; * 2\. Females aged 35-50 who are diagnosed as having uterine fibroids by transvaginal or abdominal ultrasonography; * 3\. The maximum average diameter of intramural myoma is ≤ 4cm，≥ 1cm; The amount of myoma is less than 4; * 4\. Serum 25-hydroxyvitamin D3 \< 30 ng/ml, ≥ 12 ng/ml. Exclusion Criteria: * 1\. Patients with heavy menstrual bleeding (\>80.0 mL), menstrual disorders, pelvic discomfort, infertility, or other indications for operation; * 2\. Patients complicated with myoma degeneration and adenomyosis that were suspected or diagnosed by ultrasound or gynecologic examination; * 3\. Allergic to vitamin D3; * 4\. Use of sexual hormone, mifepristone, gonadotropin-releasing hormone agonist (GnRHa), or other medication which is likely to interfere with uterine fibroids within 3 months; * 5\. Pregnancy, lactation, postmenopause, or planned pregnancy within two years; * 6\. Suspected or identified as other tumors of genital tract; * 7\. History of osteoporosis or vitamin D deficiency taking vitamin D supplements within previous one month; * 8\. History of autoimmune diseases, infectious diseases (tuberculosis, AIDS), autoimmune diseases, digestive system diseases (malabsorption, crohn disease, and dysentery); * 9\. Alanine aminotransferase (ALT) or aspartate transaminase(AST) more than 3 times of the normal upper limit, total bilirubin (TBIL) more than 2 times of the normal upper limit; * 10\. Creatinine levels≥1.4 mg/dL (123μmol/L) or creatinine clearance ≤ 50 mL/min; * 11\. History of malignant tumors; * 12\. Simultaneous participation in another clinical study with investigational medicinal product(s) or researcher thinks the subjects are not suitable for this trial.